

Andrew Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10655744/publications.pdf>

Version: 2024-02-01

17
papers

2,084
citations

687363

13
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

5013
citing authors

#	ARTICLE	IF	CITATIONS
1	Spinal anesthesia in a designated block bay for total joint arthroplasty: improving operating room efficiency. <i>Regional Anesthesia and Pain Medicine</i> , 2020, 45, 975-978.	2.3	5
2	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. <i>Nature Communications</i> , 2020, 11, 435.	12.8	47
3	MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 621-632.	6.4	29
4	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. <i>European Journal of Human Genetics</i> , 2019, 27, 308-316.	2.8	28
5	Hypermethylation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	1.3	174
6	Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, 3269-3283.	2.9	58
7	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. <i>Nature Communications</i> , 2015, 6, 5899.	12.8	162
8	DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. <i>Nature Communications</i> , 2015, 6, 7758.	12.8	105
9	Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. <i>Clinical Epigenetics</i> , 2015, 7, 52.	4.1	26
10	Endocrine therapy: defining the path of least resistance. <i>Breast Cancer Research</i> , 2014, 16, 101.	5.0	2
11	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1874-1885.	4.1	45
12	Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer. <i>Epigenomics</i> , 2013, 5, 595-598.	2.1	8
13	Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1488-1499.	4.1	129
14	Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e40466.	2.5	54
15	Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 175-198.	0.4	52
16	Cyclin D as a therapeutic target in cancer. <i>Nature Reviews Cancer</i> , 2011, 11, 558-572.	28.4	1,159
17	The Dark Side of Antihormonal Action in Breast Cancer. , 2009, , 63-84.		1